Tyra Biosciences’ (TYRA) “Buy” Rating Reiterated at HC Wainwright

Posted by George Bondi on Sep 7th, 2026

HC Wainwright restated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $45.00 target price on the stock.

Other analysts also recently issued reports about the company. Wolfe Research assumed coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. JonesTrading started coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 price target on the stock. Finally, Bank of America increased their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.22.

Check Out Our Latest Stock Analysis on Tyra Biosciences

Tyra Biosciences Stock Performance

Shares of TYRA opened at $28.65 on Friday. Tyra Biosciences has a twelve month low of $11.70 and a twelve month high of $40.65. The stock’s 50 day moving average is $29.02 and its two-hundred day moving average is $32.05. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.94 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, sell-side analysts predict that Tyra Biosciences will post -2.74 EPS for the current year.

Institutional Trading of Tyra Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in TYRA. Walleye Capital LLC acquired a new stake in shares of Tyra Biosciences during the 2nd quarter worth about $11,112,000. 5AM Venture Management LLC acquired a new position in shares of Tyra Biosciences in the second quarter valued at approximately $32,875,778. Seven Fleet Capital Management LP raised its position in shares of Tyra Biosciences by 149.6% in the first quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company’s stock valued at $7,606,000 after buying an additional 119,025 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Tyra Biosciences by 448.0% during the first quarter. Bank of America Corp DE now owns 209,922 shares of the company’s stock valued at $8,040,000 after buying an additional 171,612 shares during the period. Finally, Algert Global LLC lifted its stake in shares of Tyra Biosciences by 27.2% during the second quarter. Algert Global LLC now owns 239,120 shares of the company’s stock valued at $7,637,000 after buying an additional 51,110 shares during the period. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.